Search NASA⌕ Search

SEARCH · Search NASA

Results for “thyroid”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 415 records · Page 23

SU-F-T-117: A Pilot Study of Organ Dose Reconstruction for Wilms Tumor Patients Treated with Radiation Therapy

Purpose: To reconstruct major organ doses for the Wilms tumor pediatric patients treated with radiation therapy using pediatric computational phantoms, treatment planning system (TPS), and Monte Carlo (MC) dose calculation methods. Methods: A total of ten female and male pediatric patients (15–88 months old) were selected from the National Wilms Tumor Study cohort and ten pediatric computational phantoms corresponding to the patient’s height and weight were selected for the organ dose reconstruction. Treatment plans were reconstructed on the computational phantoms in a Pinnacle TPS (v9.10) referring to treatment records and exported into DICOM-RT files, which were then used to generate the input files for XVMC MC code. The mean doses to major organs and the dose received by 50% of the heart were calculated and compared between TPS and MC calculations. The same calculations were conducted by replacing the computational human phantoms with a series of diagnostic patient CT images selected by matching the height and weight of the patients to validate the anatomical accuracy of the computational phantoms. Results: Dose to organs located within the treatment fields from the computational phantoms and the diagnostic patient CT images agreed within 2% for all cases for both TPS and MC calculations. The maximum difference of organ doses was 55.9 % (thyroid), but the absolute dose difference in this case was 0.33 Gy which was 0.96% of the prescription dose. The doses to ovaries and testes from MC in out-of-field provided more discrepancy (the maximum difference of 13.2% and 50.8%, respectively). The maximum difference of the 50% heart volume dose between the phantoms and the patient CT images was 40.0%. Conclusion: This study showed the pediatric computational phantoms are applicable to organ doses reconstruction for the radiotherapy patients whose three-dimensional radiological images are not available.

60 APPLIED LIFE SCIENCES↗

SU-F-T-303: Quantification of MLC Positioning Accuracy in VMAT Delivery of Head and Neck Cancer Treatment

Purpose: Knowing MLC leaf positioning error over the course of treatment would be valuable for treatment planning, QA design, and patient safety. The objective of the current study was to quantify the MLC positioning accuracy for VMAT delivery of head and neck treatment plans. Methods: A total of 837 MLC log files were collected from 14 head and neck cancer patients undergoing full arc VMAT treatment on one Varian Trilogy machine. The actual and planned leaf gaps were extracted from the retrieved MLC log files. For a given patient, the leaf gap error percentage (LGEP), defined as the ratio of the actual leaf gap over the planned, was evaluated for each leaf pair at all the gantry angles recorded over the course of the treatment. Statistics describing the distribution of the largest LGEP (LLGEP) of the 60 leaf pairs including the maximum, minimum, mean, Kurtosis, and skewness were evaluated. Results: For the 14 studied patients, their PTV located at tonsil, base of tongue, larynx, supraglottis, nasal cavity, and thyroid gland with volume ranging from 72.0 cm{sup 3} to 602.0 cm{sup 3}. The identified LLGEP differed between patients. It ranged from 183.9% to 457.7% with a mean of 368.6%. For the majority of the patients, the LLGEP distributions peaked at non-zero positions and showed no obvious dependence on gantry rotations. Kurtosis and skewness, with minimum/maximum of 66.6/217.9 and 6.5/12.6, respectively, suggested relatively more peaked while right-skewed leaf error distribution pattern. Conclusion: The results indicate pattern of MLC leaf gap error differs between patients of lesion located at similar anatomic site. Understanding the systemic mechanisms underlying these observed error patterns necessitates examining more patient-specific plan parameters in a large patient cohort setting.

60 APPLIED LIFE SCIENCES↗

SU-G-IeP4-05: Experience with a Practical Approach to the Release of Radioactive Patients from Radiation Safety Isolation

Purpose: The radioactive patient releases of the nuclear medicine department in a large cancer center were analyzed to compare the estimated doses to others to the regulatory limit and institutional targets and to gauge how onerous the patients’ instructions were. Methods: In-house software that implements the NUREG 1556 approach and further considers fellow travelers, children and pregnant women and members of the public following Siegel, et al., is used to calculate release timing and to provide patients with individualized instructions. A retrospective analysis of the 218 releases in 2015 that required instructions included all I-131 and Lu-177 treatments. Results: There were 87 male and 131 female patients. They were 45.5±16.5 (8-84) years old, weighed 83.3±21.8 kg and stood 168±10 cm tall with a body mass index of 29.3±6.7 kg/m2. 195 patients received 2.96±2.23 GBq of I-131-NaI for differentiated thyroid carcinoma and eight received 636±231 MBq of I-131-NaI for hyperthyroidism. There were eight administrations of 18.5 GBq of I-131-mIBG and seven administrations of 7.4 GBq of Lu-177-DOTATATE. The dose to the most exposed person was 1.67±1.05 (mode=0.60, median=1.15) mSv. The dose to a fellow traveler was 0.31±0.31 (mode=0.1, median=0.17) mSv. The dose to children and pregnant women was 0.51±0.34 (mode=1.0, median=0.42) mSv. The duration of isolation was 7.7±17.3 (mode=2, median=1.7) hours. The duration of sleeping alone was 60.4±127 (mode=0, median=15.5) hours. The time to delay traveling was 12.2±11 (mode=median=0) hours. The time to completely avoid children and pregnant women was 23.3±26.5 (0–254, mode=median=24) hours followed by limited contact for 20.6±68.1 (0–491, mode=median=0) hours. The time to avoid others (e.g., to wait to return to work) was 12.1±101 (0–1465, mode=median=0) hours. Conclusion: The estimated doses to others were often well below the limits set by regulation, 5 mSv, or prudent practice, 1 mSv. Most patients’ instructions were not hard to comply with.

60 APPLIED LIFE SCIENCES↗

TH-AB-206-00: Challenges and Opportunities for Nuclear Medicine Theranostics

In the past few decades, the field of nuclear medicine has made long strides with the continued advancement of related sciences and engineering and the availability of diagnostic and therapeutic radionuclides. Leveraging these advancements while combining the advantages of therapeutic and diagnostic radionuclides into one radiopharmaceutical has also created a new subfield “theranostics” in nuclear medicine that has the potential to further propel the field into the future. This session is composed of two talks; one focused on the physics principles of theranostics from properties of beta and alpha emitting radionuclides to dosimetric models and quantification; while the second describes preclinical and clinical applications of theranostics and discusses the challenges and opportunities of bringing them to the clinic. At the end of the session the listener should be able to identify: The different properties of beta and alpha emitting radionuclides Which radionuclides are selected for which nuclear medicine therapies and why How PET can be used to accurately quantify the uptake of tumor targeting molecules How individualized dosimetry can be performed from the management of thyroid cancer to novel radiolabeled antibody therapies Promising pre-clinical radiopharmaceutical pairs in prostate cancer and melanoma. Promising clinical Theranostics in neuroendocrine cancers. Challenges of bringing Theranostics to the clinic. E. Delpassand, RITA Foundation -Houston; SBIR Grant; CEO and share holder of RadioMedix.

61 RADIATION PROTECTION AND DOSIMETRY↗

TH-AB-206-01: Advances in Radionuclide Therapy - From Radioiodine to Nanoparticles

In the past few decades, the field of nuclear medicine has made long strides with the continued advancement of related sciences and engineering and the availability of diagnostic and therapeutic radionuclides. Leveraging these advancements while combining the advantages of therapeutic and diagnostic radionuclides into one radiopharmaceutical has also created a new subfield “theranostics” in nuclear medicine that has the potential to further propel the field into the future. This session is composed of two talks; one focused on the physics principles of theranostics from properties of beta and alpha emitting radionuclides to dosimetric models and quantification; while the second describes preclinical and clinical applications of theranostics and discusses the challenges and opportunities of bringing them to the clinic. At the end of the session the listener should be able to identify: The different properties of beta and alpha emitting radionuclides Which radionuclides are selected for which nuclear medicine therapies and why How PET can be used to accurately quantify the uptake of tumor targeting molecules How individualized dosimetry can be performed from the management of thyroid cancer to novel radiolabeled antibody therapies Promising pre-clinical radiopharmaceutical pairs in prostate cancer and melanoma. Promising clinical Theranostics in neuroendocrine cancers. Challenges of bringing Theranostics to the clinic. E. Delpassand, RITA Foundation -Houston; SBIR Grant; CEO and share holder of RadioMedix.

60 APPLIED LIFE SCIENCES↗

TH-AB-206-02: Nuclear Medicine Theronostics: Wave of the Future; Pre-Clinical and Clinical Opportunities

In the past few decades, the field of nuclear medicine has made long strides with the continued advancement of related sciences and engineering and the availability of diagnostic and therapeutic radionuclides. Leveraging these advancements while combining the advantages of therapeutic and diagnostic radionuclides into one radiopharmaceutical has also created a new subfield “theranostics” in nuclear medicine that has the potential to further propel the field into the future. This session is composed of two talks; one focused on the physics principles of theranostics from properties of beta and alpha emitting radionuclides to dosimetric models and quantification; while the second describes preclinical and clinical applications of theranostics and discusses the challenges and opportunities of bringing them to the clinic. At the end of the session the listener should be able to identify: The different properties of beta and alpha emitting radionuclides Which radionuclides are selected for which nuclear medicine therapies and why How PET can be used to accurately quantify the uptake of tumor targeting molecules How individualized dosimetry can be performed from the management of thyroid cancer to novel radiolabeled antibody therapies Promising pre-clinical radiopharmaceutical pairs in prostate cancer and melanoma. Promising clinical Theranostics in neuroendocrine cancers. Challenges of bringing Theranostics to the clinic. E. Delpassand, RITA Foundation -Houston; SBIR Grant; CEO and share holder of RadioMedix.

61 RADIATION PROTECTION AND DOSIMETRY↗

TH-EF-207A-02: Imaging Pancreatic Î{sup 2}-Cell Function with 51/52Mn-PET

Purpose: To image β-cells noninvasively using radio-manganese PET and to develop efficient small cyclotron production of {sup 51}Mn (t1/2=46m, β{sup +}=97%) and {sup 52}Mn (t1/2=5.6d, β{sup +}=29%). Methods: {sup 51}Mn and {sup 52}Mn were produced by 16 MeV proton irradiation (GE PETtrace) of electrodeposited {sup 54}Fe on silver and Cr metal pressed into a silver disc, respectively. {sup 51}Mn was radiochemically isolated from target material by anion exchange chromatography and {sup 52}Mn was isolated by ethanolic anion exchange trap-and-release. A final injectable product of {sup 51}Mn{sup 2+} or {sup 52}Mn{sup 2+} was obtained in 0.01M pH 6.0 NaOAc. To assess pancreatic uptake, fasted ICR mice were administered and intravenous bolus or infusion of {sup 52}Mn{sup 2+}. Additionally, to demonstrate the correlation between β-cell function and {sup 52}Mn{sup 2+} pancreatic uptake, prior to tracer administration groups of ICR mice were administered glibenclamide (5mg/kg) and diazoxide (20 mg/kg) as an insulin release stimulator and blocker, respectively. To validate PET ROI quantification, ex vivo biodistribtution studies were conducted on each subject after the final imaging time-point. Results: Dynamic PET data using a left atrium ROI revealed that {sup 52}Mn{sup 2+} cleared from the blood with a 10 second half-life. Significant uptake was seen in the pancreas (approximately 20% ID/g, SUVmean= 5.5), liver, kidneys, intestine, heart, and thyroid. Pancreatic uptake was found to be highly sensitive to volatile anesthesia administration (p=0.0002), insulin release stimulation by glibenclamide (p=0.017), and by insulin release inhibition by diazoxide (p=0.046). Excellent agreement was found between in vivo PET ROI quantification and ex vivo biodistribution measurements. Conclusion: This work demonstrates the feasibility of using radiomanganese-PET for measuring functional β-cell mass in vivo. The decay characteristics and dosimetric properties of {sup 51}Mn are well suited for clinical PET, which will allow for rapid translation and application.

60 APPLIED LIFE SCIENCES↗

An organ and effective dose study of XVI and OBI cone‐beam CT systems

The main purpose of this work was to quantify patient organ doses from the two kilovoltage cone beam computed tomography (CBCT) systems currently available on medical linear accelerators, namely the X‐ray Volumetric Imager (XVI, Elekta Oncology Systems) and the On‐Board Imager (OBI, Varian Medical Systems). Organ dose measurements were performed using a fiber‐optic coupled (FOC) dosimetry system along with an adult male anthropomorphic phantom for three different clinically relevant scan sites: head, chest, and pelvis. The FOC dosimeter was previously characterized at diagnostic energies by Hyer et al. [Med Phys 2009;36(5):1711–16] and a total uncertainty of approximately 4% was found for in‐phantom dose measurements. All scans were performed using current manufacturer‐installed clinical protocols and appropriate bow‐tie filters. A comparison of image quality between these manufacturer‐installed protocols was also performed using a Catphan 440 image quality phantom. Results indicated that for the XVI, the dose to the lens of the eye (1.07 mGy) was highest in a head scan, thyroid dose (19.24 mGy) was highest in a chest scan, and gonad dose (29 mGy) was highest in a pelvis scan. For the OBI, brain dose (3.01 mGy) was highest in a head scan, breast dose (5.34 mGy) was highest in a chest scan, and gonad dose (34.61 mGy) was highest in a pelvis scan. Image quality measurements demonstrated that the OBI provided superior image quality for all protocols, with both better spatial resolution and low‐contrast detectability. The measured organ doses were also used to calculate a reference male effective dose to allow further comparison of the two machines and imaging protocols. The head, chest, and pelvis scans yielded effective doses of 0.04, 7.15, and 3.73 mSv for the XVI, and 0.12, 1.82, and 4.34 mSv for the OBI, respectively. PACS number: 87.57.uq

62 RADIOLOGY AND NUCLEAR MEDICINE↗

First PET Imaging Studies With 63 Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease

Abnormalities in zinc homeostasis are indicated in many human diseases, including Alzheimer disease (AD). 63 Zn-zinc citrate was developed as a positron emission tomography (PET) imaging probe of zinc transport and used in a first-in-human study in 6 healthy elderly individuals and 6 patients with clinically confirmed AD. A dynamic PET imaging of the brain was performed for 30 minutes following intravenous administration of 63 Zn-zinc citrate (~330 MBq). Subsequently, body PET images were acquired. Urine and venous blood were analyzed to give information on urinary excretion and pharmacokinetics. Regional cerebral 63 Zn clearances were compared with 11 C-Pittsburgh Compound B ( 11 C-PiB) and 18 F-fluorodeoxyglucose ( 18 F-FDG) imaging data. 63 Zn-zinc citrate was well tolerated in human participants with no adverse events monitored. Tissues of highest uptake were liver, pancreas, and kidney, with moderate uptake being seen in intestines, prostate (in males), thyroid, spleen, stomach, pituitary, and salivary glands. Moderate brain uptake was observed, and regional dependencies were observed in 63 Zn clearance kinetics in relationship with regions of high amyloid-β plaque burden ( 11 C-PiB) and 18 F-FDG hypometabolism. In conclusion, zinc transport was successfully imaged in human participants using the PET probe 63 Zn-zinc citrate. Primary sites of uptake in the digestive system accent the role of zinc in gastrointestinal function. Preliminary information on zinc kinetics in patients with AD evidenced regional differences in clearance rates in correspondence with regional amyloid-β pathology, warranting further imaging studies of zinc homeostasis in patients with AD.

62 RADIOLOGY AND NUCLEAR MEDICINE↗

Stress Drivers of Glucose Dynamics during Ozone Exposure Measured Using Radiotelemetry in Rats

Inhaled irritant air pollutants may trigger stress-related metabolic dysfunction associated with altered circulating adrenal-derived hormones. We used implantable telemetry in rats to assess real-time changes in circulating glucose during and after exposure to ozone and mechanistically linked responses to neuroendocrine stress hormones. First, using a cross-over design, we monitored glucose during ozone exposures (0.0, 0.2, 0.4, and 0.8 ppm) and nonexposure periods in male Wistar Kyoto rats implanted with glucose telemeters. A second cohort of unimplanted rats was exposed to ozone (0.0, 0.4 or 0.8 ppm) for 30 min, 1 h, 2 h, or 4 h with hormones measured immediately post exposure. We assessed glucose metabolism in sham and adrenalectomized rats, with or without supplementation of adrenergic/glucocorticoid receptor agonists, and in a separate cohort, antagonists. Ozone (0.8 ppm) was associated with significantly higher blood glucose and lower core body temperature beginning 90 min into exposure, with reversal of effects 4–6 h post exposure. Glucose monitoring during four daily 4-h ozone exposures revealed duration of glucose increases, adaptation, and diurnal variations. Ozone-induced glucose changes were preceded by higher levels of adrenocorticotropic hormone, corticosterone, and epinephrine but lower levels of thyroid-stimulating hormone, prolactin, and luteinizing hormones. Higher glucose and glucose intolerance were inhibited in rats that were adrenalectomized or treated with adrenergic plus glucocorticoid receptor antagonists but exacerbated by agonists. We demonstrated the temporality of neuroendocrine-stress–mediated biological sequalae responsible for ozone-induced glucose metabolic dysfunction and mechanism in a rodent model.

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTAN↗

Longitudinal Assessment of Lung Cancer Progression in Mice Using the Sodium Iodide Symporter Reporter Gene and SPECT/CT Imaging

Lung cancer has the highest mortality rate of any tissue-specific cancer in both men and women. Research continues to investigate novel drugs and therapies to mitigate poor treatment efficacy, but the lack of a good descriptive lung cancer animal model for preclinical drug evaluation remains an obstacle. Here we describe the development of an orthotopic lung cancer animal model which utilizes the human sodium iodide symporter gene (hNIS; SLC5A5) as an imaging reporter gene for the purpose of non-invasive, longitudinal tumor quantification. hNIS is a glycoprotein that naturally transports iodide (I- ) into thyroid cells and has the ability to symport the radiotracer 99mTc-pertechnetate ( 99mTcO4 - ). A549 lung adenocarcinoma cells were genetically modified with plasmid or lentiviral vectors to express hNIS. Modified cells were implanted into athymic nude mice to develop two tumor models: a subcutaneous and an orthotopic xenograft tumor model. Tumor progression was longitudinally imaged using SPECT/CT and quantified by SPECT voxel analysis. hNIS expression in lung tumors was analyzed by quantitative real-time PCR. Additionally, hematoxylin and eosin staining and visual inspection of pulmonary tumors was performed. We observed that lentiviral transduction provided enhanced and stable hNIS expression in A549 cells. Furthermore, 99mTcO4 - uptake and accumulation was observed within lung tumors allowing for imaging and quantification of tumor mass at twotime points. This study illustrates the development of an orthotopic lung cancer model that can be longitudinally imaged throughout the experimental timeline thus avoiding inter-animal variability and leading to a reduction in total animal numbers. Furthermore, our orthotopic lung cancer animal model is clinically relevant and the genetic modification of cells for SPECT/CT imaging can be translated to other tissue-specific tumor animal models.

60 APPLIED LIFE SCIENCES↗

Background and Derivation of ANS-5.4 Standard Fission Product Release Model

This background report describes the technical basis for the newly proposed American Nuclear Society (ANS) 5.4 standard, Methods for Calculating the Fractional Release of Volatile Fission Products from Oxide Fuels. The proposed ANS 5.4 standard provides a methodology for determining the radioactive fission product releases from the fuel for use in assessing radiological consequences of postulated accidents that do not involve abrupt power transients. When coupled with isotopic yields, this method establishes the "gap activity," which is the inventory of volatile fission products that are released from the fuel rod if the cladding is breached. Best-estimate and conservative upper-bound 95/95 tolerance models for predicting the release of volatile radioactive isotopes of krypton, xenon, and iodine are described. The isotope that provides the most significant contribution to equivalent dose to individuals is generally I-131 for accidents that occur during in-reactor operation or shortly after reactor operation (e.g., the fuel-handling accident) due to its dose to the thyroid. The existing conservative upper-bound model for predicting the I-131 release has been shown to be very conservative in comparison to the available measured release data for I-131. The 2009 model proposed herein predicts up to a factor of 2 lower release than the old ANS 5.4 release model.

22 GENERAL STUDIES OF NUCLEAR REACTORS↗

Collaborative Research: Natural Organic Matter and Microbial Controls on Mobilization/Immobilization of I and Pu in Soils and Waters Affected by Radionuclide Releases in USA and Japan

In this project, the relationship between natural organic matter (NOM) and two radioactive elements that are relevant to nuclear waste disposal were studied: Plutonium (Pu) and Iodine. The human and environmental risks associated with Pu stem mainly from the very long half-lives of several of its isotopes ( 238 Pu, 88 yr; 239 Pu, 24,100 yr; 240 Pu, 6560 yr) and its radiotoxicity. Understanding Pu biogeochemical behavior in both near-field (>10-11M) and far-field scales (<10-11M) is imperative to the development of approaches for reprocessing Pu, remediation of Pu contamination and accurate assessment of risks posed by disposal practices for Pu-bearing wastes. The environmental mobility of Pu can be affected by redox potential, pH, adsorption, precipitation, complexation, colloid formation, and microbial activity, of which the first characteristic has the most profound influence. Numerous studies have shown high affinity of Pu towards NOM, as well as to mineral phases. NOM is ubiquitous in the environment, e.g., both fulvic and humic acids are able to reduce Pu(V,VI) to Pu(IV) and the redox potential of NOM is positively related to the abundance of phenolic/acidic OH groups. NOM can either facilitate or limit actinide migration, depending on specific biogeochemical conditions including pH, mineral and organic matter characteristics, etc. The other radionuclide of interest is radioiodine ( 129 I). 129I is a major by-product of nuclear fission and of serious concern to the Department of Energy (DOE) as it is among the top risk drivers at existing and potential radiowaste-contaminated sites. The risk of 129 I stems largely from its high bioconcentration factor (90% of the body’s iodine is accumulated in the thyroid), a high inventory at source terms, a very long-half life (16M years), and rapid mobility in the subsurface environment. As a consequence, 129 I has the lowest drinking water standard (1 pCi/L) among all radionuclides in the Federal Register. With a novel and sensitive gas chromatography-mass spectrometry (GC-MS) method developed in our lab, it is possible to quickly and simultaneously determine the distribution of 129 I and stable 127 I forms in environments, as low as 2 pCi/L for 129 I. This method was subsequently validated using accelerator mass spectroscopy, AMS. IO 3 - and organo-I were determined as major species in the groundwater of SRS and the Hanford Site, contrary to thermodynamic predictions that I- should be the dominant species at these sites. Mobility of 129 I was also demonstrated to depend greatly on the I species and its concentration, sediment pH, and redox state, with times to achieve equilibrium taking up to 12 weeks. Along the groundwater pathway in the F-Area of SRS, 129 I- supplied from the seepage basins was transformed to 129 IO 3 - and organo- 129 I with increasing iodine sediment sorption, causing the lower total 127 I and 129 I concentrations along the gradient transect of the waste plume. By contrast, groundwater 129 I concentrations in the wetlands (as high as 1617.3 pCi/L) were greatly elevated with respect to the source term (159.3 pCi/L). While the NOM promoted the uptake of 129 I to the wetland sediment, it also promoted the formation of soluble organic fraction. A small fraction of NOM that is bound to iodine can behave as a mobile organo-I source. Iodide was enzymatically incorporated into NOM, whereas both iodide and iodate were abiotically bound to NOM, under certain conditions. Iodate removal from the mobile aqueous phase can also occur through incorporation into carbonate (e.g., at the Hanford Site, USA). Thus immobilization and re-mobilization of iodine species were influenced by pH, Eh and the presence of NOM and metal oxides, which adds to the complexity of site remediation action. A ground-breaking result was to elucidate the products (i.e. organo-iodine moieties formed via enzymatic and non-enzymatic processes) at the molecular level by nuclear magnetic resonance (NMR) and electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry (ESI-FTICRMS). We found that iodine-NOM interactions may be influenced by NOM hydrophobic aliphatic moieties. From the perspective of ESI-FTICRMS, organo-iodine formulas were ascribed to the groups of unsaturated hydrocarbons, lignins and proteins. Iodate is likely abiotically reduced to reactive iodine species by lignin- and tannin-like compounds or carboxylic-rich alicyclic molecules (CRAM). We also investigated microbial mechanisms in iodine incorporation into NOM. We established that soil bacteria isolated from F-Area of SRS did not accumulate significant amounts of I- (0.2-2%). Intracellular uptake of I- decreases with increasing pH when pH ranged from 4 to 6. In contrast, 44 out of 84 strains isolated from the F-Area of SRS can transform I- to IO 3 - and organo-iodine. In some cases, oxidation was facilitated in the presence of H 2 O 2 . Microbes can also excrete organic acids that enhance I- oxidation by lowering the ambient pH and reacting with H 2 O 2 to form peroxy carboxylic acids. At lower pH values (≤5), H 2 O 2 hydrolysis was the driving force for iodide-oxidation; whereas, at pH ≥ 6, spontaneous decomposition of peroxy carboxylic acids, originating from H 2 O 2 and organic acids were the primary cause of iodide oxidation. Lastly, it was determined that microbial processes involved in Mn (II) are capable of directly oxidizing I- via enzymatic catalysis (i.e., multicopper oxidases), or indirectly through the formation of reactive oxygen species (ROS) and/or biogenic manganese oxides. ROS-mediated oxidation of I- was found to predominate at pH >5, whereas the enzymatic and Mn oxide pathways were more active at pH < 5. Together, this project has resulted in 9 publications in high-impact journals, and the training of 1 Ph.D and 4 undergraduate students.

54 ENVIRONMENTAL SCIENCES↗

Using Radioiodine Speciation to Address Environmental Remediation and Waste Stream Sequestration Problems at the Fukushima Daiichi Nuclear Power Plant and a DOE Site

Iodine-129 ( 129 I), with a half-life of half-life of 16 million years, is commonly considered the single greatest risk driver in high-level and low-level nuclear repositories. This risk stems from several basic properties of 129 I, and under many geochemical conditions, it can move as an anion at nearly the rate of water through the subsurface environment. 129 I is also extremely radiologically toxic because over 90% of body burden accumulates in the thyroid, which weighs only about 14g in an adult. There is also a large worldwide inventory of radioiodine as a result of its high fission yield and this inventory is rapidly increasing as a result of nuclear energy production. Radioiodine is produced at a rate of 40 GBq (1 Ci) per gigawatt of electricity produced by nuclear power. To illustrate how the properties of 129 I magnify its risk, 129 I accounts for only 0.00002% of the radiation released from the Savannah River Site in Aiken, South Carolina, but contributes 13% of the population dose, a six orders of magnitude magnification of risk with respect to its radioactivity. The currently favored solid phase for LLW immobilization is cement, while HLW immobilization is the incorporation of waste into glass (vitrification). However, so far, the incorporation into cement and subsequent leaching of only iodide has been seriously investigated. The major problem with this approach is that it ignores the complex speciation of iodine, i.e., it ignores iodate and organo-iodine which have different chemistries. Most of the past research was devoted to the mechanism of iodide uptake in cement hydrate phases that is sorption and/or incorporation. Very few data exist on iodate and organo-iodine incorporation in cement, even though large quantities of liquid waste containing also radioiodine have already been solidified in cement Iodine-129 from low-level waste is commonly disposed of in cementitious materials. Grout, a dense cementitious fluid, mixed with a reducing slag, is often used to immobilize radionuclides. However, the reducing environment might not be conducive to immobilize iodine. For example, the silver based immobilization technologies (e.g., AgCl, Ag-impregnated granular activated carbon, Ag-mordenite) remove iodine from the aqueous phase by promoting the formation of Ag-iodide precipitates. The solubility of AgI is eight orders of magnitude lower than it is for AgIO 3 . Similarly, coprecipitation of iodine into calcium carbonate phases occurs only with IO 3 - and not with I - and org-I. If one would want to immobilize iodine more effectively, different engineering approaches would need to be used to promote binding of I - , IO 3 - , or organo-I. Using laboratory experiments with grout, slag, and silver-based adsorbents, and GC-MS and I K-edge XANES and EXAFS and C K-edge XANES spectroscopy for identifying iodine speciation, the major problems with these methods have been identified as focused too much on just one of the iodine species for immobilization, while others, especially organo-I, remained mobile. Finally, we established that most of the adsorbents that are used contain sufficient amounts of organic matter to create organo-I . It is anticipated that increased attention directed at understanding and quantifying the speciation of radioiodine, as opposed to simply total radioiodine, will lead to improved remediation results to be used for long-term radioiodine disposal in cementitious waste forms.

129-Iodine↗

Early Lab scientists had questions, Plastic Man gave them answers

He was a willing subject in countless scientific experiments, a superstar of health physics, as well as a favorite photo prop -- and not just around Halloween time. He was Plastic Man. Beginning in the mid-1950s, the Lab (then called Los Alamos Scientific Laboratory) often relied on several life-sized synthetic test subjects to avoid experimenting on people. In the early days of the Laboratory, not much was known about how different radioisotopes interacted with the human body and how much it absorbed from different radiation sources. Answering queries like these is where Plastic Man came in. For example, during the 1950s and 1960s, the Lab was tasked with developing nuclear rockets for space exploration under the Rover Program. One of the concerns was how astronauts might be affected when exposed to radiation from these rocket engines. So, the Lab’s health group set up an experiment in which Plastic Man was placed in close proximity to an experimental Rover nuclear rocket engine. Running experiments like this using Plastic Man kept humans safer. How life-like was he? There were actually two variations of Plastic Man. Both had hard plastic exteriors, but one of the models encased a real human skeleton. They also had movable joints and simulated organs, such as a liver, a spleen, kidneys, lungs and a thyroid. Although Plastic Man in its entirety was used in experiments, much of the data collected were from research conducted inside on these replicated organs. In time, technology advanced and Plastic Man was able to retire from the Lab. He found a new home in 1964 as a display at the Laboratory’s science museum, and is sometimes displayed today in the Bradbury Science Museum in downtown Los Alamos.

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTAN↗

Requirements and Conceptual Design of Off-gas Systems for the Reprocessing of Metallic Fuels

An assessment has been conducted to determine how key regulations regarding volatile radionuclide emissions to the atmosphere may apply to the off-gas streams associated with electrochemical reprocessing. The scope of this assessment was based upon a generic electrochemical reprocessing scheme with a throughput rate of 200 MTIHM/y applied to metallic fuel discharged from a sodium fast reactor (SFR), but the findings are able to be translated to other advanced nuclear scenarios as merited. Air dispersion modeling was performed using the EPA CAP-88 model and evaluated the uncontrolled decontamination factors (DFs) that would be required to achieve regulatory compliance with the dose-based limits set forth by EPA regulation 40 CFR 190.10(a). These DFs were compared to those required by fuel cycle–based limits set forth by EPA regulation 40 CFR 190.10(b). Two theoretical sites with disparate climatological conditions were selected for air dispersion modeling (Idaho and Tennessee). The radionuclides modeled included 3 H, 85 Kr, 129 I, and selected alpha-emitting transuranic isotopes (referred to here as 239 Pu-TRU <1y ). It was found that the fuel cycle-based limits in 40 CFR 190.10(b) are most restrictive for 85 Kr and 239 Pu-TRU <1y , with DFs of 3 and 6.1E+09, respectively. The dose-based limit as derived from 40 CFR 190.10(a) could require mitigation of tritium in some scenarios, with an estimated DF of about 3 for the reference scenarios. The fuel cycle-based limit for 129 I resulted in a DF of about 240 for the reference scenario. The need for iodine mitigation based on dose to the public depended upon the physical form of iodine as either particulate or vapor-phase species. Emission of iodine from the facility as a vapor necessitated DFs of about 2 but emission as a particulate would require DFs >6,000 to meet thyroid dose-based limits. Effects of physical form on needed iodine mitigation are significant, but the understanding of speciation of iodine both during electrochemical reprocessing and after release to the atmosphere is limited. The electrochemical processing unit operations were evaluated to identify potential release points for the volatile radionuclides and to assess the potential for retention of the radionuclides within the process (thus decreasing the need for mitigation). Mitigation strategies for 3 H, 85 Kr, 129 I, and 239 Pu-TRU <1y were identified. In all cases, there are reasonably achievable pathways to regulatory compliance, although in some cases additional R&D is merited to verify the chemical speciation of these isotopes and to develop and demonstrate potential treatment technologies for this application. Whether or not additional off-gas controls (beyond common operations such as HEPA filtration and oxygen and moisture control) are needed for any of these regulated or volatile radionuclides depends on the (a) type of facility (NRC-regulated or DOE), (b) used fuel process rate, (c) used fuel burnup and composition, (d) speciation and retention of volatile radionuclides in the process and in the cell gas cleanup system, (e) site-specific parameters such as location, meteorology, stack height, and site boundaries, and (f) levels of conservatism and safety factors used in assessing compliance to air emissions regulations. Performance of this assessment revealed several areas where information is lacking or additional research is required in order to better determine if or what kinds of off-gas control might be needed. First, and most significantly, the understanding of the chemical speciation and physical form and partitioning of iodine during electrochemical processing operations is lacking and prevents the ability to accurately assess the potential iodine mitigation requirements. Future research in this area should be multifaceted and include thermodynamic modeling of iodine speciation in different process steps, experiments to quantify the kinetics of vapor-phase and melt-phase transitions, bench-scale experiments to determine the potential chemical and physical form of iodine emissions from the electrorefining process, and verification of iodine behavior with experiments utilizing operational facilities. Similarly, an improved understanding of iodine behavior in the environment after release from the facility stack will be required to refine dose estimations, as particulate and vapor-phase emissions result in significantly different doses to the MEI.

11 NUCLEAR FUEL CYCLE AND FUEL MATERIALS↗

Quantitative Evaluation of Potassium Iodide Implementation Strategies for Emergency Preparedness and Response

This study evaluates the effectiveness of potassium iodide (KI) distribution strategies in mitigating exposure to radioiodine during severe nuclear power plant accidents. This analysis quantitatively compares various KI distribution methods (pre-distributed versus stockpiles), including scenarios with and without KI administration. The results indicate that differences in distribution strategies impact the projected thyroid dose by at least an order of magnitude. The results also indicate that the timing of KI administration is critical, as expected. For scenarios involving delayed releases of significant quantities of radionuclides, evacuation is the most effective protection strategy regardless of KI distribution method. For scenarios involving rapid releases, retrieving KI from stockpiles can have a detrimental effect. Pre-distributed KI is potentially the most effective approach when used as a supplement to evacuation and sheltering. However, these model results are based on idealized conditions for KI distribution and administration; the actual benefits of KI prophylaxis are likely to be less than estimated in this report due to many variables. The results highlight the importance of considering the cost and rigor of different distribution programs and public compliance with emergency instructions. This report includes suggested research to explore KI distribution plans for advanced reactors.

59 BASIC BIOLOGICAL SCIENCES↗

Multi-Color Spectral Transcript Analysis (SPECTRA) for Phenotypic Characterization of Tumor Cells

Many human tumors show significant changes in their signal transduction pathways and, thus, the way the cells interact with their environment. Often caused by chromosomal rearrangements, including gene amplifications, translocations or deletions, the altered levels of gene expression may provide a tumor-specific signature that can be exploited for diagnostic or therapeutic purposes. We investigated the utility of multiplexed fluorescence in situ hybridization (FISH) using non-isotopically labeled cDNA probes detected by Spectral Imaging as a sensitive and rapid procedure to measure tumor-specific gene expression signatures. We used a commercially available system to acquire and analyze multicolor FISH images. Initial investigations used panels of fluorescent calibration standards to evaluate the system. These experiments were followed by hybridization of five-to-six differently labeled cDNA probes, which target the transcripts of tyrosine kinase genes known to be differently expressed in normal cells and tumors of the breast or thyroid gland. The relatively simple, yet efficient, molecular cytogenetic method presented here may find many applications in characterization of solid tumors or disseminated tumor cells. Addressing tumor heterogeneity by means of multi-parameter single cell analyses is expected to enable a wide range of investigations in the areas of tumor stem cells, tumor clonality and disease progression.

59 BASIC BIOLOGICAL SCIENCES↗